Abstract |
Infantile malignant osteopetrosis (IMO) is a fatal disease caused by lack of functional osteoclasts, and the only available treatment is hematopoietic stem cell (HSC) transplantation. In the majority of patients, the TCIRG1 gene, coding for a subunit of a proton pump essential for bone resorption, is mutated. Oc/oc mice have a deletion in the homologue gene (tcirg1) and die at 3 to 4 weeks, but can be rescued by neonatal transplantation of HSCs. Here, HSC-targeted gene therapy of osteopetrosis in the oc/oc mouse model was developed. Oc/oc fetal liver cells depleted of Ter119-expressing erythroid cells were transduced with a retroviral vector expressing tcirg1 and GFP, and subsequently transplanted intraperitoneally to irradiated neonatal oc/oc mice. Eight of 15 mice survived past the normal life span of oc/oc mice. In vitro osteoclastogenesis revealed formation of GFP-positive osteoclasts and bone resorption, albeit at a lower level than from wild-type cells. The skeletal phenotype was analyzed by X-ray and histopathology and showed partial correction at 8 weeks and almost normalization after 18 weeks. In summary, osteopetrosis in oc/oc mice can be reversed by neonatal transplantation of gene-modified HSCs leading to long-term survival. This represents a significant step toward the development of gene therapy for osteopetrosis.
|
Authors | Maria K Johansson, Teun J de Vries, Ton Schoenmaker, Mats Ehinger, Ann C M Brun, Anders Fasth, Stefan Karlsson, Vincent Everts, Johan Richter |
Journal | Blood
(Blood)
Vol. 109
Issue 12
Pg. 5178-85
(Jun 15 2007)
ISSN: 0006-4971 [Print] United States |
PMID | 17332244
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Atp6ap1 protein, mouse
- Vacuolar Proton-Translocating ATPases
|
Topics |
- Animals
- Animals, Newborn
- Disease Progression
- Genetic Therapy
(methods)
- Hematopoietic Stem Cell Transplantation
(methods)
- Mice
- Mice, Mutant Strains
- Osteopetrosis
(therapy)
- Sequence Deletion
- Survival Rate
- Vacuolar Proton-Translocating ATPases
(administration & dosage, genetics)
|